image: Correlative light and electronmicroscopy (CLEM) images of MXL vesicle (left). Arrowhead indicates the disassembled aggregates; PB, p-body; Ly,lysosome. A cover art transforms this microscopic discovery into a vibrant underwater scene through the innocent yet insightful eyes of a child.
Credit: Ming-Xi Liu and Jing-Ci Liu.
Mastering the storage and activation of mRNA represents one of the core and most fascinating scientific mysteries in cellular differentiation. Scientists have long wondered how, at critical moments of development or differentiation, cells precisely awaken these “dormant” mRNAs and translate them into the proteins essential for supporting life. Recently, research focused on spermatogenesis has uncovered an intriguing molecular mechanism. Scientists discovered that, as sperm mature, a new cellular structure—the MXL vesicle (MEX3D-associated lysosomal vesicle)—along with the MX-H (MEX3D-HIP1) pathway, acts as the machinery that precisely controls the release of “silenced” mRNAs.
Unlocking the Secrets of Precise mRNA Activation
Sperm formation is a complex process. As sperm cells mature, they go through several stages. In the later stages, called spermatogenesis, round spermatids (immature sperm cells) become elongated spermatids (mature sperm cells). Although these cells stop making new RNA during this transition, they still need to produce new proteins to complete their development. To solve this challenge, the cells cleverly make the necessary RNA in advance, store it, and then activate it for protein production just when it’s needed. Researchers mapped out which RNAs are present and active during these critical stages.
They found that certain RNAs essential for sperm maturation are only translated into proteins after a process called nuclear condensation (when the sperm cell’s nucleus becomes tightly packed). By examining the molecules that interact with these RNAs, the team identified a protein called MEX3D as a key player. MEX3D is present only in the later stages of sperm development and has special enzyme activity (E3 ligase) that can tag other proteins for degradation.
To understand MEX3D’s role, researchers studied mice lacking this protein. Without MEX3D, sperm development was severely disrupted: the cells failed to remove extra cytoplasm, couldn’t form the proper mitochondrial sheath, and had trouble releasing mature sperm, leading to abnormal sperm shape and function. The study showed that MEX3D is essential for activating the translation of stored RNAs during sperm maturation.
The “Switch” That Awakens Dormant mRNA
MEX3D works by tagging certain RNA-binding proteins (like SF-1, a splicing regulator) for degradation. It does this by first binding to them via the RNA molecules. If MEX3D is missing, these inhibitory proteins build up, blocking the activation of critical RNAs. Experiments revealed that when SF-1 is overabundant, the important RNAs remain inactive.
The researchers discovered that MEX3D teams up with other proteins, such as HIP1, to direct the tagged RNA-binding proteins into special vesicles called MXL(MEX3D-associated lysosomal) vesicles. These vesicles eventually merge with lysosomes, the cell’s recycling centers, breaking down the inhibitors and freeing the RNAs for use.
Tumor Cells “Hijack” the Germline Mechanism
Even more remarkably, this mechanism—originally restricted to male germ cells—is “hijacked” by cancers such as gastric cancer to enhance tumor growth. Studies have shown that MEX3D is significantly upregulated in gastric cancer tissue, and interfering with its function can effectively inhibit cancer cell proliferation. Because the MXL vesicle system and its pathway are physiologically exclusive to spermatogenesis, targeting this machinery holds promise for developing anti-cancer strategies that are both highly selective and have minimal side effects. Thus, this research not only provides crucial insight into mRNA regulatory mechanisms during development, but also bridges the fields of reproductive biology and tumor proteostasis, paving the way for innovative, safe, and effective cancer therapies.
About the study
This study was conducted jointly by Nanjing Medical University, Anhui Medical University, and Shanghai Jiao Tong University School of Medicine. Core laboratories involved include the State Key Laboratory of Reproductive Medicine and Offspring Health, the NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, and the Reproductive Medicine Center of Shanghai General Hospital. This work was supported by grants from the National Natural Science Foundation of China, the National Key R&D Program of China, the Natural Science Foundation of Jiangsu Province, and the Natural Science Foundation of Anhui Province.